Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986249

Next Previous
Drug Profile

BMS 986249

Alternative Names: Anti-CTLA-4 Probody - Bristol-Myers Squibb; Anti-CTLA-4 Probody IO - Bristol-Myers Squibb; BMS-986249; CTLA-4-directed probody therapeutic

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CytomX Therapeutics
  • Developer Bristol-Myers Squibb
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma; Solid tumours

Most Recent Events

  • 09 Sep 2022 Efficacy, pharmacodynamics, pharmacokinetics and adverse events data from a phase I/IIa trial in Solid tumours presented at 47th European Society for Medical Oncology Congress
  • 13 Jun 2022 Phase-II clinical trials in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Germany, Finland, Romania, Canada, Poland, Chile, Australia, Spain, Italy, Argentina, USA (Parenteral) (CytomX Therapeutics pipeline, June 2022)
  • 13 Jun 2022 Phase-II clinical trials in Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Recurrent) in USA, Australia, Argentina, Chile, Canada, Germany, Italy, Spain, Finland, Poland, Romania (Parenteral) (CytomX Therapeutics pipeline, June 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top